Skip to content
OpenCapital
Get started

Seres Therapeutics MCRB Q3 2025 earnings

Reported November 5, 2025 · Before market open

Revenue$351.0KMiss by $7.5M
EPS$0.94Beat by $0.89
Revenue estimate$7.8M
EPS estimate$0.05

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$179.0K
EPS estimate-$2.19

Versus estimates

Revenue

Q1 2026$358.0KIn lineQ4 2025$438.0KMiss by $4.9M
Q3 2025$351.0KMiss by $7.5M

Diluted EPS

Q1 2026-$2.08Miss by $0.20Q4 2025-$1.89Beat by $0.50
Q3 2025$0.94Beat by $0.89
Q2 2025-$2.27Beat by $0.45Q1 2025-$2.24Miss by $1.57Q4 2024-$0.32Miss by $0.15

Ask the moment Seres Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Seres Therapeutics report Q3 2025 earnings?
Seres Therapeutics (MCRB) reported Q3 2025 earnings on November 5, 2025 before market open.
What were Seres Therapeutics's Q3 2025 revenue and EPS?
Seres Therapeutics reported revenue of $351.0K and eps of $0.94 for Q3 2025.
Did Seres Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $7.8M by $7.5M. EPS beat the consensus estimate of $0.05 by $0.89.
Where can I find Seres Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-265708) and the 10-Q periodic report (0001193125-25-266011) directly on SEC EDGAR. The filing index links above go to sec.gov.